IDegLira improves long-term health outcomes and reduces costs for diabetes patients
Conclusión Clave:
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Estudio de un Vistazo
Participantes
Intervención
IDegLira
Resultados
Cumulative incidence of background retinopathy, Cumulative incidence of proliferative retinopathy, Cumulative incidence of macular edema, Cumulative incidence of severe vision loss, Cumulative incidence of neuropathy, Cumulative incidence of proteinuria, Cumulative incidence of end-stage renal disease, Cumulative incidence of ischemic heart disease, Cumulative incidence of heart failure, Cumulative incidence of myocardial infarction, HbA1c, BMI, Systolic blood pressure, Diastolic blood pressure, Hypoglycemia events
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
HbA1c decreased by 0.6% (p<0.0001)
Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
Cumulative incidence of eye diseases decreased by up to 41.1%
Cumulative incidence of neuropathy decreased by 17.3%
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 IDegLira (Medications) |  BMI (Weight & Anthropometrics) | No Change | Unclear |
IDegLira (Medications) |  Diabetic neuropathy incidence (Clinical Outcomes) | Decrease | Strong |
IDegLira (Medications) | Diabetic retinopathy incidence (Clinical Outcomes) | Decrease | Strong |
IDegLira (Medications) |  Diastolic blood pressure (Metabolic Health) | No Change | Unclear |
IDegLira (Medications) |  HbA1c (Glycemic Control) | Decrease | Strong |
IDegLira (Medications) |  Hypoglycemia events (Safety) | No Change | Unclear |
IDegLira (Medications) | Incidence heart disease (Clinical Outcomes) | Decrease | Strong |
IDegLira (Medications) | Incidence of heart failure (Clinical Outcomes) | Decrease | Strong |
IDegLira (Medications) |  Incidence of macular edema (Patient-Reported) | Decrease | Strong |
IDegLira (Medications) | Incidence of myocardial infarction (Clinical Outcomes) | Decrease | Strong |
IDegLira (Medications) | Incidence of proteinuria (Metabolic Health) | Decrease | Strong |
IDegLira (Medications) | Incidence vision loss (Patient-Reported) | Decrease | Strong |
IDegLira (Medications) | Renal and urinary disorders incidence (Safety) | Decrease | Strong |
IDegLira (Medications) | Systolic blood pressure (Metabolic Health) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
La Evidencia Sugiere
- HbA1c decreased by 0.6% (p<0.0001)
- Systolic blood pressure decreased by 3.5 mmHg (p=0.0017)
- Cumulative incidence of eye diseases decreased by up to 41.1%
- Cumulative incidence of neuropathy decreased by 17.3%
Tener en Cuenta
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Entre Líneas
- The study may have limited generalizability to populations outside China.
- Potential unmeasured confounders could affect the outcomes.
- The analysis did not include long-term follow-up data beyond the initial study period.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Referencia de la Revista
Dunming X, Junling W, Lei Z, et al. Long-term cost-effectiveness of IDegLira versus GLP-1RA added to basal insulin regimen for patients with type 2 diabetes in China. PLOS ONE. 2025. doi:10.1371/journal.pone.0310497
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.